FDG (18F‑FDG) is a radiolabeled glucose analogue used in PET‑CT scans. Injected intravenously, cells take it up like glucose and it becomes metabolically trapped after phosphorylation, allowing imaging of tissue metabolic activity. Areas with increased uptake often indicate cancer, inflammation, or infection. Its positron emission enables PET detection; the tracer has a short half‑life, so imaging is done promptly.

Cost varies by country and facility. In the US a FDG PET‑CT commonly ranges roughly $2,000–$6,000 (higher in some hospitals). In the UK it’s free on the NHS but privately typically £700–£1,500. In India prices often range about ₹8,000–35,000. Final price depends on tracer dose, imaging protocol, whether it’s a hospital or private diagnostic centre, and insurance.

PET is the imaging technique that uses radioactive tracers to visualize physiological processes. FDG PET is a specific PET scan using 18F‑FDG, a glucose analog, to map tissue glucose metabolism. FDG PET commonly detects cancer, infection, and inflammation. Other PET tracers target different molecules or receptors for particular diseases (e.g., amyloid, PSMA, somatostatin).

An FDG PET scan is generally not painful. You’ll get an intravenous radiotracer injection that may cause brief stinging or minor bruising. Lying still in the scanner can be uncomfortable or trigger claustrophobia for some, but the imaging itself is painless. Side effects are uncommon, and staff will explain the procedure and help with any discomfort or concerns.

FDG PET scans are generally safe. They use a small amount of radioactive glucose and give a low, short-lived radiation dose, comparable to a CT. Adverse reactions are rare; injection-site pain, mild allergic responses, or transient increased blood sugar may occur. Avoid unless essential during pregnancy; breastfeeding may need a brief pause. Discuss diabetes, medications, and recent imaging with your doctor.

A positive PET scan shows areas of increased metabolic activity that may indicate cancer, infection, or inflammation. It prompts your doctor to correlate findings with symptoms, other imaging, and laboratory tests. Often further evaluation—additional scans, biopsy, or specialist referral—is needed to confirm the cause. Results also help stage disease and guide treatment planning. False positives can occur, so diagnosis relies on combined clinical assessment.